Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Background - A subgroup of patients with HER2-positive metastatic gastric and gastroesophageal junction cancers shows long-term response under trastuzumab maintenance monotherapy. Obviously, HER2 status alone is not able to identify these patients. We performed this study to identify potential new p...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 2023
|
| In: |
European journal of cancer
Year: 2023, Jahrgang: 183, Pages: 119-130 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2023.01.022 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2023.01.022 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923000461 
|
| Verfasserangaben: | Isabel Porth, Daniela Hirsch, Yonca Ceribas, Philip Weidner, Wilko Weichert, Thorsten Oliver Götze, Sven Perner, Kim Luley, Christian Moritz Heyer, Carolina de la Torre, Ralf-Dieter Hofheinz, Sylvie Lorenzen, Timo Gaiser |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1845703448 | ||
| 003 | DE-627 | ||
| 005 | 20251119190643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230519s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.01.022 |2 doi | |
| 035 | |a (DE-627)1845703448 | ||
| 035 | |a (DE-599)KXP1845703448 | ||
| 035 | |a (OCoLC)1389530122 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Porth, Isabel |d 1993- |e VerfasserIn |0 (DE-588)120988559X |0 (DE-627)1697803202 |4 aut | |
| 245 | 1 | 0 | |a Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma |c Isabel Porth, Daniela Hirsch, Yonca Ceribas, Philip Weidner, Wilko Weichert, Thorsten Oliver Götze, Sven Perner, Kim Luley, Christian Moritz Heyer, Carolina de la Torre, Ralf-Dieter Hofheinz, Sylvie Lorenzen, Timo Gaiser |
| 264 | 1 | |c April 2023 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.05.2023 | ||
| 520 | |a Background - A subgroup of patients with HER2-positive metastatic gastric and gastroesophageal junction cancers shows long-term response under trastuzumab maintenance monotherapy. Obviously, HER2 status alone is not able to identify these patients. We performed this study to identify potential new prognostic biomarkers for this long-term responding patient group. - Patients and methods - Tumour samples of 19 patients with HER2-positive metastatic gastric and gastroesophageal junction cancer who underwent trastuzumab treatment were retrospectively collected from multiple centres. Patients were divided into long-term responding (n = 7) or short-term responding group (n = 12) according to progression-free survival (PFS≥12 months vs. PFS < 12 months). Next-generation sequencing and microarray-based gene expression analysis were performed along with HER2 and PD-L1 immunohistochemistry. - Results - Long-term responding patients had significantly higher PD-L1 combined positive scores (CPS) and CPS correlated with longer progression-free survival. PD-L1 positivity (CPS ≥ 1) was further associated with an increased CD4+ memory T-cell score. The ERBB2 copy number as well as the tumour mutational burden could not discriminate between short-term and long-term responding patients. Genetic alterations and coamplifications in HER2 pathway associated genes such as EGFR, which were connected to trastuzumab resistance, were present in 10% of the patients and equally distributed between the groups. - Conclusion - The study highlights the clinical relevance of PD-L1 testing also in the context of trastuzumab treatment and offers a biological rational by demonstrating elevated CD4+ memory T-cells scores in the PD-L1-positive group. | ||
| 650 | 4 | |a Gastric cancer | |
| 650 | 4 | |a HER2 | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a Prognostic factor | |
| 650 | 4 | |a Trastuzumab | |
| 700 | 1 | |a Hirsch, Daniela |d 1987- |e VerfasserIn |0 (DE-588)1070596620 |0 (DE-627)824096347 |0 (DE-576)431928525 |4 aut | |
| 700 | 1 | |a Ceribas, Yonca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weidner, Philip |d 1987- |e VerfasserIn |0 (DE-588)1151598216 |0 (DE-627)101194216X |0 (DE-576)497900327 |4 aut | |
| 700 | 1 | |a Weichert, Wilko |d 1970-2023 |e VerfasserIn |0 (DE-588)123509106 |0 (DE-627)56134650X |0 (DE-576)293740461 |4 aut | |
| 700 | 1 | |a Götze, Thorsten |d 1976- |e VerfasserIn |0 (DE-588)131855964 |0 (DE-627)515807745 |0 (DE-576)298796600 |4 aut | |
| 700 | 1 | |a Perner, Sven Roger |d 1972- |e VerfasserIn |0 (DE-588)124400086 |0 (DE-627)363321047 |0 (DE-576)294154477 |4 aut | |
| 700 | 1 | |a Luley, Kim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heyer, Christian Moritz |d 1993- |e VerfasserIn |0 (DE-588)1382013515 |0 (DE-627)194162488X |4 aut | |
| 700 | 1 | |a Torre, Carolina de la |d 1985- |e VerfasserIn |0 (DE-588)1122355831 |0 (DE-627)875651283 |0 (DE-576)481254137 |4 aut | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 700 | 1 | |a Lorenzen, Sylvie |d 1973- |e VerfasserIn |0 (DE-588)128891106 |0 (DE-627)384629202 |0 (DE-576)297385739 |4 aut | |
| 700 | 1 | |a Gaiser, Timo |d 1975- |e VerfasserIn |0 (DE-588)1030402280 |0 (DE-627)735221685 |0 (DE-576)378226533 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 183(2023), Seite 119-130 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma |
| 773 | 1 | 8 | |g volume:183 |g year:2023 |g pages:119-130 |g extent:12 |a Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2023.01.022 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804923000461 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230519 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1030402280 |a Gaiser, Timo |m 1030402280:Gaiser, Timo |d 60000 |d 63400 |e 60000PG1030402280 |e 63400PG1030402280 |k 0/60000/ |k 1/60000/63400/ |p 13 |y j | ||
| 998 | |g 128891106 |a Lorenzen, Sylvie |m 128891106:Lorenzen, Sylvie |p 12 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 11 | ||
| 998 | |g 1122355831 |a Torre, Carolina de la |m 1122355831:Torre, Carolina de la |d 60000 |d 60200 |d 60210 |e 60000PT1122355831 |e 60200PT1122355831 |e 60210PT1122355831 |k 0/60000/ |k 1/60000/60200/ |k 2/60000/60200/60210/ |p 10 | ||
| 998 | |g 1382013515 |a Heyer, Christian Moritz |m 1382013515:Heyer, Christian Moritz |d 140000 |e 140000PH1382013515 |k 0/140000/ |p 9 | ||
| 998 | |g 123509106 |a Weichert, Wilko |m 123509106:Weichert, Wilko |p 5 | ||
| 998 | |g 1151598216 |a Weidner, Philip |m 1151598216:Weidner, Philip |d 60000 |d 61100 |e 60000PW1151598216 |e 61100PW1151598216 |k 0/60000/ |k 1/60000/61100/ |p 4 | ||
| 998 | |g 1070596620 |a Hirsch, Daniela |m 1070596620:Hirsch, Daniela |p 2 | ||
| 998 | |g 120988559X |a Porth, Isabel |m 120988559X:Porth, Isabel |d 60000 |e 60000PP120988559X |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1845703448 |e 4323636784 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"recId":"266883400","origin":[{"dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1992"}],"id":{"issn":["1879-0852"],"eki":["266883400"],"zdb":["1468190-0"]},"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"pubHistory":["28.1992 -"],"part":{"year":"2023","volume":"183","text":"183(2023), Seite 119-130","pages":"119-130","extent":"12"},"language":["eng"],"titleAlt":[{"title":"EJC online"}],"disp":"Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinomaEuropean journal of cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}]}],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"April 2023"}],"title":[{"title_sort":"Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma","title":"Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"12 S."}],"id":{"eki":["1845703448"],"doi":["10.1016/j.ejca.2023.01.022"]},"recId":"1845703448","person":[{"role":"aut","family":"Porth","given":"Isabel","display":"Porth, Isabel"},{"display":"Hirsch, Daniela","given":"Daniela","role":"aut","family":"Hirsch"},{"display":"Ceribas, Yonca","given":"Yonca","role":"aut","family":"Ceribas"},{"role":"aut","family":"Weidner","display":"Weidner, Philip","given":"Philip"},{"display":"Weichert, Wilko","given":"Wilko","family":"Weichert","role":"aut"},{"display":"Götze, Thorsten","given":"Thorsten","role":"aut","family":"Götze"},{"family":"Perner","role":"aut","given":"Sven Roger","display":"Perner, Sven Roger"},{"given":"Kim","display":"Luley, Kim","family":"Luley","role":"aut"},{"role":"aut","family":"Heyer","given":"Christian Moritz","display":"Heyer, Christian Moritz"},{"family":"Torre","role":"aut","display":"Torre, Carolina de la","given":"Carolina de la"},{"role":"aut","family":"Hofheinz","given":"Ralf-Dieter","display":"Hofheinz, Ralf-Dieter"},{"family":"Lorenzen","role":"aut","display":"Lorenzen, Sylvie","given":"Sylvie"},{"role":"aut","family":"Gaiser","display":"Gaiser, Timo","given":"Timo"}],"note":["Gesehen am 19.05.2023"],"name":{"displayForm":["Isabel Porth, Daniela Hirsch, Yonca Ceribas, Philip Weidner, Wilko Weichert, Thorsten Oliver Götze, Sven Perner, Kim Luley, Christian Moritz Heyer, Carolina de la Torre, Ralf-Dieter Hofheinz, Sylvie Lorenzen, Timo Gaiser"]},"language":["eng"]} | ||
| SRT | |a PORTHISABECOMPREHENS2023 | ||